The EPS projection of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for quarter ended 2016-09-30 is $2.07. A week before, the EPS forecast was $2.07 against target of $2.07, a month earlier. This estimate stood at $2.07 60 days earlier versus forecast of $2.07 90 days earlier, confirming a deviation of 0%.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 2, 0 and 1, respectively.
The downgrade of EPS estimates for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the preceding 120, 60, 30 and 90 days were 2, 0, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was $2.07. This projection was computed after accounting 3 calls. As reported on 2016-05-10 the EPS was $1.87. The change was $0.56, demonstrating a percentage deviation of 42.75%. The projections confirmed a standard deviation of 0.1.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands at $417.051 and the median estimate at $418.207. Almost 4 analysts announced their estimates.
The highest estimate is $422.7 while the lowest target is $409.09 showing standard deviation of 5.716%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of -0.826%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stated that the change in forecast was 1.624%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...